1. Bertolote JM, Fleischmann A. A global perspective in the epidemiology of suicide. Suicidology 2002;7:6–8.
2. Hawton K, van Heeringen K. Suicide. Lancet 2009;373:1372–1381.
4. Stone DM, Holland KM, Bartholow B, Crosby AE, Davis S, Wilkins N. Preventing Suicide: A Technical Package of Policies, Programs, and Practices. Atlanta, GA, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention. 2017;Available at:
https://www.cdc.gov/violenceprevention/pdf/suicideTechnicalPackage.pdf. Accessed June 10, 2019.
6. Andrade L, Caraveo-anduaga JJ, Berglund P, Bijl RV, Graaf RD, Vollebergh W, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;12:3–21.
8. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 2013;43:471–481.
9. Mann JJ. A current perspective of suicide and attempted suicide. Ann Intern Med 2002;136:302–311.
10. Coryell W, Young EA. Clinical predictors of suicide in primary major depressive disorder. J Clin Psychiatry 2005;66:412–417.
11. Ponsoni A, Branco LD, Cotrena C, Shansis FM, Grassi-Oliveira R, Fonseca RP. Self-reported inhibition predicts history of suicide attempts in bipolar disorder and major depression. Compr Psychiatry 2018;82:89–94.
13. Abreu LN, Oquendo MA, Galfavy H, Burke A, Grunebaum MF, Sher L, et al. Are comorbid anxiety disorders a risk factor for suicide attempts in patients with mood disorders? A two-year prospective study. Eur Psychiatry 2018;47:19–24.
14. Pompili M, Serafini G, Innamorati M, Möller-Leimkühler AM, Giupponi G, Girardi P, et al. The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention. Eur Arch Psychiatry Clin Neurosci 2010;260:583–600.
16. Van Heeringen K, Mann JJ. The neurobiology of suicide. Lancet Psychiatry 2014;1:63–72.
18. Eikelenboom M, Beekman ATF, Penninx BWJH, Smit JH. A 6-year longitudinal study of predictors for suicide attempts in major depressive disorder. Psychol Med 2019;49:911–921.
19. Brent DA, Mann JJ. Family genetic studies, suicide, and suicidal behavior. Am J Med Genet Part C. Semin Med Genet 2005;133C:13–24.
20. Statham DJ, Heath AC, Madden PA, Bucholz KK, Bierut L, Dinwiddie SH, et al. Suicidal behaviour: an epidemiological and genetic study. Psychol Med 1998;28:839–855.
22. Fu Q, Heath AC, Bucholz KK, Nelson EC, Glowinski AL, Goldberg J, et al. A twin study of genetic and environmental influences on suicidality in men. Psychol Med 2002;32:11–24.
23. Voracek M, Loibl LM. Genetics of suicide: a systematic review of twin studies. Wien Klin Wochenschr 2007;119:463–475.
27. Willour VL, Seifuddin F, Mahon PB, Jancic D, Pirooznia M, Steele J, et al. A genome-wide association study of attempted suicide. Mol Psychiatry 2012;17:433–444.
28. Mullins N, Perroud N, Uher R, Butler AW, Cohen-Woods S, Rivera M, et al. Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: a genome-wide association and polygenic scoring study. Am J Med Genet B Neuropsychiatr Genet 2014;165B:428–437.
29. Galfalvy H, Haghighi F, Hodgkinson C, Goldman D, Oquendo MA, Burke A, et al. A genome-wide association study of suicidal behavior. Am J Med Genet B Neuropsychiatr Genet 2015;168:557–563.
32. Butler AW, Breen G, Tozzi F, Craddock N, Gill M, Korszun A, et al. A genomewide linkage study on suicidality in major depressive disorder confirms evidence for linkage to 2p12. Am J Med Genet B Neuropsychiatr Genet 2010;153B:1465–1473.
33. Erlangsen A, Appadurai V, Wang Y, Turecki G, Mors O, Werge T, et al. Genetics of suicide attempts in individuals with and without mental disorders: a population-based genome-wide association study. Mol Psychiatry 2018;[Epub ahead of print].
34. Ruderfer DM, Walsh CG, Aguirre MW, Tanigawa Y, Ribeiro JD, Franklin JC, et al. Significant shared heritability underlies suicide attempt and clinically predicted probability of attempting suicide. Mol Psychiatry 2019;[Epub ahead of print].
35. Hirata T, Otsuka I, Okazaki S, Mouri K, Horai T, Boku S, et al. Major depressive disorder-associated SIRT1 locus affects the risk for suicide in women after middle age. Psychiatry Res 2019;278:141–145.
36. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009;34(Suppl 1):S186–S195.
37. Fries GR, Gassen NC, Rein T. The FKBP51 Glucocorticoid receptor co-chaperone: regulation, function, and implications in health and disease. Int J Mol Sci 2017;18(12):pii: E2614.
38. Zannas AS, Wiechmann T, Gassen NC, Binder EB. Gene-stress-epigenetic regulation of fkbp5: clinical and translational implications. Neuropsychopharmacology 2016;41:261–274.
41. Tozzi L, Carballedo A, Wetterling F, McCarthy H, O’Keane V, Gill M, et al. Single-nucleotide polymorphism of the fkbp5 gene and childhood maltreatment as predictors of structural changes in brain areas involved in emotional processing in depression. Neuropsychopharmacology 2016;41:487–497.
42. Yeo S, Enoch MA, Gorodetsky E, Akhtar L, Schuebel K, Roy A, et al. The influence of FKBP5 genotype on expression of FKBP5 and other glucocorticoidregulated genes, dependent on trauma exposure. Genes Brain Behav 2017;16:223–232.
43. Hernández-Díaz Y, González-Castro TB, Tovilla-Zárate CA, Juárez- Rojop IE, López-Narváez ML, Pérez-Hernández N, et al. Association between FKBP5 polymorphisms and depressive disorders or suicidal behavior: a systematic review and meta-analysis study. Psychiatry Res 2019;271:658–668.
44. Gonda X, Fountoulakis KN, Harro J, Pompili M, Akiskal HS, Bagdy G, et al. The possible contributory role of the S allele of 5-HTTLPR in the emergence of suicidality. J Psychopharmacol 2011;25:857–866.
45. Antypa N, Serretti A, Rujescu D. Serotonergic genes and suicide: a systematic review. Eur Neuropsychopharmacol 2013;23:1125–1142.
46. Daws LC, Toney GM. High-Speed Chronoamperometry to Study Kinetics and Mechanisms for Serotonin Clearance in Vivo. In: Michael AC, Borland LM, editor. Electrochemical Methods for Neuroscience. Florida: Boca Raton, 2007, p. 63–81.
47. Purselle DC, Nemeroff CB. Serotonin transporter: a potential substrate in the biology of suicide. Neuropsychopharmacology 2003;28:613–619.
49. Fanelli G, Serretti A. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2019;88:375–387.
51. Turecki G, Ernst C, Jollant F, Labonté B, Mechawar N. The neurodevelopmental origins of suicidal behavior. Trends Neurosci 2012;35:14–23.
55. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597–606.
56. Arato M, Banki CM, Bissette G, Nemeroff CB. Elevated CSF CRF in suicide victims. Biol Psychiatry 1989;25:355–359.
57. Coryell W, Schlesser M. The dexamethasone suppression test and suicide prediction. Am J Psychiatry 2001;158:748–753.
58. Kunugi H, Urushibara T, Nanko S. Combined DEX/CRH test among Japanese patients with major depression. J Psychiatr Res 2004;38:123–128.
59. Yerevanian BI, Feusner JD, Koek RJ, Mintz J. The dexamethasone suppression test as a predictor of suicidal behavior in unipolar depression. J Affect Disord 2004;83:103–108.
60. Jokinen J, Nordström AL, Nordström P. ROC analysis of dexamethasone suppression test threshold in suicide prediction after attempted suicide. J Affect Disord 2008;106:145–152.
61. Underwood MD, Khaibulina AA, Ellis SP, Moran A, Rice PM, Mann JJ, et al. Morphometry of the dorsal raphe nucleus serotonergic neurons in suicide victims. Biol Psychiatry 1999;46:473–483.
62. Boldrini M, Underwood MD, Mann JJ, Arango V. More tryptophan hydroxylase in the brainstem dorsal raphe nucleus in depressed suicides. Brain Res 2005;1041:19–28.
64. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Arch Gen Psychiatry 1976;33:1193–1197.
65. Mann JJ, Arango V, Marzuk PM, Theccanat S, Reis DJ. Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br J Psychiatry Suppl 1989;(8):7–14.
66. Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Kelly TM, et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000;57:729–738.
67. Hou C, Jia F, Liu Y, Li L. CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Brain Res 2006;1095:154–158.
68. Leake A, Fairbairn AF, McKeith IG, Ferrier IN. Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates. Psychiatry Res 1991;39:155–165.
69. Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, et al. Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 1990;47:1038–1047.
70. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Pandey SC, Pesold C, et al. Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 2002;159:419–429.
71. Mann JJ, Currier D, Stanley B, Oquendo MA, Amsel LV, Ellis SP. Can biological tests assist prediction of suicide in mood disorders? Int J Neuropsychopharmacol 2006;9:465–474.
72. Gaysina D, Zainullina A, Gabdulhakov R, Khusnutdinova E. The serotonin transporter gene: polymorphism and haplotype analysis in Russian suicide attempters. Neuropsychobiology 2006;54:70–74.
73. Agargun MY, Cartwright R. REM sleep, dream variables and suicidality in depressed patients. Psychiatry Res 2003;119:33–39.
74. Singareddy RK, Balon R. Sleep and suicide in psychiatric patients. Ann Clin Psychiatry 2001;13:93–101.
75. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50:260–265.
76. Chen YY, Lu TH. Suicide prevention is not just about treating depression. Inj Prev 2006;12:208
77. Grah M, Mihanovic M, Ruljancic N, Restek-Petrovic B, Molnar S, Jelavic S. Brain-derived neurotrophic factor as a suicide factor in mental disorders. Acta Neuropsychiatr 2014;26:356–363.
80. Castren E, Kojima M. Brain-derived neurotrophic factor in mood disorders and antidepressant treatments. Neurobiol Dis 2017;97:119–126.
81. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59:1116–1127.
82. Huang TL, Lee CT. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res 2006;40:664–668.
83. Dwivedi Y. Brain-Derived Neurotrophic Factor in Suicide Pathophysiology. The Neurobiological Basis of Suicide. Florida: Boca Raton (FL); 2012.
84. Garcia R. Stress, synaptic plasticity, and psychopathology. Rev Neurosci 2002;13:195–208.
85. Wagner G, Schultz CC, Koch K, Schachtzabel C, Sauer H, Schlosser RG. Prefrontal cortical thickness in depressed patients with high-risk for suicidal behavior. J Psychiatr Res 2012;46:1449–1455.
86. Sher L. Brain-derived neurotrophic factor and suicidal behavior. QJM 2011;104:455–458.
87. Paska AV, Zupanc T, Pregelj P. The role of brain-derived neurotrophic factor in the pathophysiology of suicidal behavior. Psychiatr Danub 2013;25(Suppl 2):S341–S344.
88. Lee BH, Kim YK. Potential peripheral biological predictors of suicidal behavior in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:842–847.
89. Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, et al. Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:78–85.
91. Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999;46:1181–1191.
92. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001;7:541–547.
94. Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim Y, Tsan G, et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry 2002;7:579–593.
95. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activitydependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257–269.
96. Dowlatshahi D, MacQueen GM, Wang JF, Reiach JS, Young LT. G Protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide, and treatment at the time of death. J Neurochem 1999;73:1121–1126.
97. Dwivedi Y, Rao JS, Rizavi HS, Kotowski J, Conley RR, Roberts RC, et al. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003;60:273–282.
98. Young LT, Bezchlibnyk YB, Chen B, Wang JF, MacQueen GM. Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment. Biol Psychiatry 2004;55:570–577.
99. Carlberg L, Schosser A, Calati R, Serretti A, Massat I, Papageorgiou K, et al. Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. Int J Neurosci 2015;125:336–343.
100. Martino M, Rocchi G, Escelsior A, Contini P, Colicchio S, de Berardis D, et al. NGF serum levels variations in major depressed patients receiving duloxetine. Psychoneuroendocrinology 2013;38:1824–1828.
102. Dwivedi Y, Mondal AC, Rizavi HS, Conley RR. Suicide brain is associated with decreased expression of neurotrophins. Biol Psychiatry 2005;58:315–324.
103. Diniz BS, Teixeira AL, Machado-Vieira R, Talib LL, Gattaz WF, Forlenza OV. Reduced serum nerve growth factor in patients with latelife depression. Am J Geriat Psychiatry 2013;21:493–496.
104. Wiener CD, de Mello Ferreira S, Pedrotti Moreira F, Bittencourt G, de Oliveira JF, Lopez Molina M, et al. Serum levels of nerve growth factor (NGF) in patients with major depression disorder and suicide risk. J Affect Disord 2015;184:245–248.
105. Serafini G, Pompili M, Elena Seretti M, Stefani H, Palermo M, Coryell W, et al. The role of inflammatory cytokines in suicidal behavior: a systematic review. Eur Neuropsychopharmacol 2013;23:1672–1686.
106. Black C, Miller BJ. Meta-analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients. Biol Psychiatry 2015;78:28–37.
107. Courtet P, Giner L, Seneque M, Guillaume S, Olie E, Ducasse D. Neuroinflammation in suicide: toward a comprehensive model. World J Biol Psychiatry 2016;17:564–586.
109. Vargas HO, Nunes SO, Pizzo de Castro M, Bortolasci CC, Sabbatini Barbosa D, Kaminami Morimoto H, et al. Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J Affect Disord 2013;150:923–930.
111. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–1245.
113. De Berardis D, Conti CM, Serroni N, Moschetta FS, Carano A, Salerno RM, et al. The role of cholesterol levels in mood disorders and suicide. J Biol Regul Homeost Agents 2009;23:133–140.
116. Kunugi H, Takei N, Aoki H, Nanko S. Low serum cholesterol in suicide attempters. Biol Psychiatry 1997;41:196–200.
117. Papassotiropoulos A, Hawellek B, Frahnert C, Rao GS, Rao M. The risk of acute suicidality in psychiatric inpatients increases with low plasma cholesterol. Pharmacopsychiatry 1999;32:1–4.
118. Alvarez JC, Cremniter D, Gluck N, Quintin P, Leboyer M, Berlin I, et al. Low serum cholesterol in violent but not in non-violent suicide attempters. Psychiatry Res 2000;95:103–108.
119. Kim YK, Lee HJ, Kim JY, Yoon DK, Choi SH, Lee MS. Low serum cholesterol is correlated to suicidality in a Korean sample. Acta Psychiatr Scand 2002;105:141–148.
120. Lee HJ, Kim YK. Serum lipid levels and suicide attempts. Acta Psychiatr Scand 2003;108:215–221.
121. Misiak B, Stanczykiewicz B, Laczmanski L, Frydecka D. Lipid profile disturbances in antipsychotic-naive patients with first-episode nonaffective psychosis: a systematic review and meta-analysis. Schizophr Res 2017;190:18–27.
122. Vuksan-Cusa B, Marcinko D, Nad S, Jakovljevic M. Differences in cholesterol and metabolic syndrome between bipolar disorder men with and without suicide attempts. Acta Neuropsychiatr 2009;21(Suppl 2):66–69.
123. Da Graca Cantarelli M, Nardin P, Buffon A, Eidt MC, Antonio Godoy L, Fernandes BS, et al. CA. Serum triglycerides, but not cholesterol or leptin, are decreased in suicide attempters with mood disorders. J Affect Disord 2015;172:403–409.
124. Budania S, Rathi M, Singh S, Yadav S, Mittra P. Serum cholesterol and depression: an update. Med J 2014;7:543–549.
125. Wallner B, Machatschke IH. The evolution of violence in men: the function of central cholesterol and serotonin. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:391–397.
126. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 2014;44:2029–2040.
127. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001;178:200–206.
128. Marzuk PM, Hartwell N, Leon AC, Portera L. Executive functioning in depressed patients with suicidal ideation. Acta Psychiatr Scand 2005;112:294–301.
132. Paulus MP. Cognitive control in depression and anxiety: out of control? Current Opinion in Behavioral Sciences 2015;1:113–120.
133. McGirr A, Dombrovski AY, Butters MA, Clark L, Szanto K. Deterministic learning and attempted suicide among older depressed individuals: cognitive assessment using the Wisconsin Card Sorting Task. J Psychiatr Res 2012;46:226–232.
134. Westheide J, Quednow BB, Kuhn KU, Hoppe C, Cooper-Mahkorn D, Hawellek B, et al. Executive performance of depressed suicide attempters: the role of suicidal ideation. Eur Arch Psychiatry Clin Neurosci 2008;258:414–421.
136. Gorlyn M, Keilp J, Burke A, Oquendo M, Mann JJ, Grunebaum M. Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion. Psychiatry Res 2015;225:407–412.
137. Richard-Devantoy S, Berlim M, Jollant F. A meta-analysis of neuropsychological markers of vulnerability to suicidal behavior in mood disorders. Psychol Med 2014;44:1663–1673.
138. Keilp JG, Sackeim HA, Brodsky BS, Oquendo MA, Malone KM, Mann JJ. Neuropsychological dysfunction in depressed suicide attempters. Am J Psychiatry 2001;158:735–741.
139. Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS spectrums 2013;18:139–149.
140. Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull 2013;139:81–132.
141. Bortolato B, Carvalho AF, McIntyre RS. Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. CNS Neurolog Disorders Drug Targets 2014;13:1804–1818.
143. Ho MC, Hsu YC, Lu ML, Gossop M, Chen VC. ‘Cool’ and ‘Hot’ executive functions in suicide attempters with major depressive disorder. J Affect Disord 2018;235:332–340.
144. Erić AP, Erić I, Ćurković M, Dodig-Ćurković K, Kralik K, Kovač V, et al. The temperament and character traits in patients with major depressive disorder and bipolar affective disorder with and without suicide attempt. Psychiatr Danub 2017;29:171–178.
145. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry 1993;50:975–990.
148. Bani-Fatemi A, Tasmim S, Graff-Guerrero A, Gerretsen P, Strauss J, Kolla N, et al. Structural and functional alterations of the suicidal brain: An updated review of neuroimaging studies. Psychiatry Res Neuroimaging 2018;278:77–91.
149. Desmyter S, van Heeringen C, Audenaert K. Structural and functional neuroimaging studies of the suicidal brain. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:796–808.
150. Jollant F, Lawrence NL, Olié E, Guillaume S, Courtet P. The suicidal mind and brain: a review of neuropsychological and neuroimaging studies. World J Biol Psychiatry 2011;12:319–339.
151. Van Heeringen K, Bijttebier S, Desmyter S, Vervaet M, Baeken C. Is there a neuroanatomical basis of the vulnerability to suicidal behavior? A coordinate-based meta-analysis of structural and functional MRI studies. Front Hum Neurosci 2014;22:824
153. Zhang H, Chen Z, Jia Z, Gong Q. Dysfunction of neural circuitry in depressive patients with suicidal behaviors: a review of structural and functional neuroimaging studies. Prog Neuropsychopharmacol Biol Psychiatry 2014;53:61–66.
154. Jollant F. Neuroimaging of Suicidal Behavior. In: Kaschka WP, Rujescu D, editor. Biological Aspects of Suicidal Behavior. Adv Biol Psychiatry. Basel: Karger, 2016, p. 110–122.
155. Vang FJ, Ryding E, Träskman-Bendz L, van Westen D, Lindström MB. Size of basal ganglia in suicide attempters, and its association with temperament and serotonin transporter density. Psychiatry Res 2010;183:177–179.
156. Dombrovski AY, Siegle GJ, Szanto K, Clark L, Reynolds CF, Aizenstein H. The temptation of suicide: striatal gray matter, discounting delayed rewards, and suicide attempts in late-life depression. Psychol Med 2012;42:1203–1215.
157. Peng H, Wu K, Li J, Qi H, Guo S, Chi M, et al. Increased suicide attempts in young depressed patients with abnormal temporal-parietal- limbic gray matter volume. J Affect Disord 2014;165:69–73.
158. Monkul ES, Hatch JP, Nicoletti MA, Spence S, Brambilla P, Lacerda AL, et al. Fronto-limbic brain structures in suicidal and non-suicidal female patients with major depressive disorder. Mol Psychiatry 2007;12:360–366.
161. Hwang JP, Lee TW, Tsai SJ, Chen TJ, Yang CH, Lirng JF, et al. Cortical and subcortical abnormalities in late-onset depression with history of suicide attempts investigated with MRI and voxel-based morphometry. J Geriatr Psychiatry Neurol 2010;23:171–184.
162. Gifuni AJ, Ding Y, Olié E, Lawrence N, Cyprien F, Le Bars E, et al. Subcortical nuclei volumes in suicidal behavior: nucleus accumbens may modulate the lethality of acts. Brain Imaging Behav 2016;10:96–104.
163. Lee YJ, Kim S, Gwak AR, Kim SJ, Kang SG, Na KS, et al. Decreased regional gray matter volume in suicide attempters compared to suicide non-attempters with major depressive disorders. Compr Psychiatry 2016;67:59–65.
164. Colle R, Chupin M, Cury C, Vandendrie C, Gressier F, Hardy P, et al. Depressed suicide attempters have smaller hippocampus than depressed patients without suicide attempts. J Psychiatr Res 2015;61:13–18.
165. Fan T, Wu X, Yao L, Dong J. Abnormal baseline brain activity in suicidal and non-suicidal patients with major depressive disorder. Neurosci Lett 2013;534:35–40.
166. Cao J, Chen X, Chen J, Ai M, Gan Y, Wang W, et al. Resting-state functional MRI of abnormal baseline brain activity in young depressed patients with and without suicidal behavior. J Affect Disord 2016;205:252–263.
167. Kang S, Na K, Choi J, Kim J, Son Y, Lee YJ. Resting-state functional connectivity of the amygdala in suicide attempters with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2017;77:222–227.
168. Jollant F, Lawrence NS, Giampietro V, Brammer MJ, Fullana MA, Drapier D, et al. Orbitofrontal cortex response to angry faces in men with histories of suicide attempts. Am J Psychiatry 2008;165:740–748.
169. Jollant F, Lawrence NS, Olie E, O’Daly O, Malafosse A, Courtet P, et al. Decreased activation of lateral orbitofrontal cortex during risky choices under uncertainity is associated with disadvantageous decisionmaking and suicidal behaviour. Neuroimage 2010;51:1275–1281.
170. Pan L, Segreti A, Almeida J, Jollant F, Lawrence N, Brent D, et al. Preserved hippocampal function during learning in the context of risk in adolescent suicide attempt. Psychiatry Res 2013;211:112–118.
171. Pan LA, Hassel S, Segreti AM, Nau SA, Brent DA, Phillips ML. Differential patterns of activity and functional connectivity in emotion processing neural circuitry to angry and happy faces in adolescents with and without suicide attempt. Psychol Med 2013;43:2129–2142.
173. Nye JA, Purselle D, Plisson C, Voll RJ, Stehouwer JS, Votaw JR, et al. Decreased brainstem and putamen SERT binding potential in depressed suicide attempters using 11C-zient PET imaging. Depress Anxiety 2013;30:902–907.
174. Ryding E, Ahnlide JA, Lindström M, Rosén I, Träskman-Bendz L. Regional brain serotonin and dopamine transporter binding capacity in suicide attempters relate to impulsiveness and mental energy. Psychiatry Res 2006;148:195–203.
177. Maj M. When does depression become a mental disorder? Br J Psychiatry 2011;199:85–86.
179. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington: American Psychiatric Publishing; 2013.
180. De Berardis D, Fornaro M, Valchera A, Cavuto M, Perna G, Di Nicola M, et al. Eradicating suicide at its roots: preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors. Int J Mol Sci 2018;19:pii: E2888.
181. De Berardis D, Tomasetti C, Pompili M, Serafini G, Vellante F, Fornaro M, et al. An update on glutamatergic system in suicidal depression and on the role of esketamine. Curr Top Med Chem 2020;[Epub ahead of print].
182. Hawton K, Casañas I Comabella C, Haw C, Saunders K. Risk factors for suicide in individuals with depression: a systematic review. J Affect Disord 2013;147:17–28.